NCT06532396 - A Study Evaluating Multiple Ascending Doses of QRL-101 in Healthy Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

December 20, 2024

Study Completion Date

December 20, 2024

Conditions

Healthy Volunteers

Interventions

DRUG

QRL-101

Multiple-ascending doses of QRL-101 will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.

DRUG

Placebo

Multiple-ascending doses of comparator placebo will be administered orally to healthy participants.

Trial Locations (1)

9728 NZ

ICON plc. Van Swietenlaan 6, Groningen

All Listed Sponsors

lead

QurAlis Corporation

INDUSTRY